Published: May 9, 2014 at 9:00 am

Managed by Stephen Feinberg, Cerberus Capital Management revealed a new stake in DHT Holdings Inc (NYSE:DHT), a recent 13G filing with the SEC shows. The new position amounts to 3.92 million shares with a current market value of around $29.00 million, which amounts to 5.70% of the company’s total market capitalization.

Based in Hamilton, Bermuda, DHT Holdings Inc (NYSE:DHT) is an independent crude oil tanker company. Performing trade operations internationally, its fleet consists of crude carriers in the Suezmax, Aframax, and VLCC segments. Recently, the company announced that it has purchased another VLCC built in 2004 at Daewoo for $49.00 million.

The company has delivered stable revenues in the past 5 years, generating losses of $4.13 million or $0.24 per share last year, compared to losses of $94.05 million or $7.83 per share in 2012. DHT Holdings’ stock is currently quoted at around $7.45, the company expected to produce EPS of $0.50 in 2014. Setting a target price of $10.35 per share, market analysts recommend that investors buy the company’s stock.

Kevin Michael Ulrich‘s Anchorage Advisors and Jim Simons‘ Renaissance Technologies are two other large shareholders of DHT Holdings Inc (NYSE:DHT), the former holding a position of nearly 5.00 million shares, while the latter a position of around 263,000 shares, according to their latest 13F filings.

Stephen Feinberg’s Cerberus Capital Management holds a $140.59 million equity portfolio, of which around 65.00% are invested in the Services Sector. BlueLinx Holdings Inc. (NYSE:BXC), a penny stock trading at around $1.10 per share, represents a tremendous share in the fund’s portfolio, the position amassing more than 47.10 million shares of the company. Another stock in which the fund owns a significant stake of 5.13 million shares is SandRidge Energy Inc. (NYSE:SD), an independent oil and natural gas company. A few weeks ago, Cerberus revealed a new position of 41.52 million shares in Ally Financial Inc (NYSE:ALLY).

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.